The Cancer Drug Fund (CDF) de-listing further drugs Many blood cancer patients are about to face more severe issues of access to treatment, following the announcement that the CDF is de-listing further drugs in order to balance its budget. Twelve of these are blood cancer drugs. None of the cuts affect MDS patients, but the […]